M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Capecitabine and Oxaliplatin in Adenocarcinoma of the Small Bowel and Ampulla of Vater

Phase 2

Completed

Conditions: Gastrointestinal Cancer

Interventions: Drug: Capecitabine
Drug: Oxaliplatin

First Posted Date: 2006-07-20

Last Posted Date: 2012-10-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 31

Registration Number: NCT00354887

Locations: 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States

Lenalidomide for Patients With Myelofibrosis (MF)

Phase 2

Completed

Conditions: Myelofibrosis

Interventions: Drug: Lenalidomide
Drug: Prednisone

First Posted Date: 2006-07-17

Last Posted Date: 2019-07-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT00352794

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract

Phase 2

Completed

Conditions: Gastrointestinal Cancer
Carcinoma, Neuroendocrine

Interventions: Drug: Cisplatin
Drug: Irinotecan

First Posted Date: 2006-07-17

Last Posted Date: 2012-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 21

Registration Number: NCT00353015

Locations: 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States

Experience of Brain Tumor Caregivers

Completed

Conditions: Brain Cancer
Glioma

Interventions: Behavioral: Interview
Behavioral: Questionnaire

First Posted Date: 2006-07-17

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT00352820

Locations: 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States

Experience of Having Chronic Graft-Versus-Host Disease

Completed

Conditions: Graft-Versus-Host Disease

Interventions: Behavioral: Interview
Behavioral: Questionnaire

First Posted Date: 2006-07-17

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 187

Registration Number: NCT00353106

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss

Phase 3

Completed

Conditions: Non-Hodgkin's Lymphoma
Lymphoma

Interventions: Drug: Zoledronic Acid
Drug: Vitamin D
Drug: Calcium Carbonate

First Posted Date: 2006-07-17

Last Posted Date: 2013-07-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 135

Registration Number: NCT00352846

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Gemox as First and Second Line Therapy in Unknown Primary Cancer

Phase 2

Completed

Conditions: Unknown Primary Neoplasms

Interventions: Drug: Gemcitabine (Gemox)
Drug: Oxaliplatin
Behavioral: Questionnaire

First Posted Date: 2006-07-17

Last Posted Date: 2012-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 29

Registration Number: NCT00353145

Locations: 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States

Effects of Cancer Symptoms on Caregivers

Completed

Conditions: Psychosocial

Interventions: Behavioral: Phenomenological Interviews
Behavioral: Quantitative Interviews

First Posted Date: 2006-07-14

Last Posted Date: 2022-02-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 199

Registration Number: NCT00351988

Locations: 🇺🇸
Lyndon Baines Johnson Hospital, Houston, Texas, United States
🇺🇸
Jackson Memorial, Miami, Florida, United States
🇺🇸
Ben Taub General Hospital, Houston, Texas, United States

and more 1 locations

The Effect of Donepezil on Sedation and Other Symptoms

Phase 3

Terminated

Conditions: Advanced Cancer

Interventions: Drug: Placebo
Drug: Donepezil

First Posted Date: 2006-07-14

Last Posted Date: 2016-05-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 27

Registration Number: NCT00352664

Locations: 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States

Vanguard Study for Head and Neck Cancer or Non-Small Cell Lung Cancer (NSCLC) Patients

Completed

Conditions: Lung Cancer
Head and Neck Cancer

Interventions: Other: Assessments

First Posted Date: 2006-07-14

Last Posted Date: 2016-02-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 54

Registration Number: NCT00352391

Locations: 🇺🇸
Eisenhower Army Medical Center, Fort Gordon, Georgia, United States
🇺🇸
Conemaugh Memorial Medical Center, Johnstown, Pennsylvania, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy